

Special Issue

The Effect of Radiation Therapy on the Tumor Ecosystem

Message from the Guest Editor

Radiotherapy is used in more than 50% of cancer patients with curative and/or palliative intent, making it one of the most common and powerful treatments. Whereas the killing of clonogenic tumor cells remains the primary goal, the biological response of the tumor microenvironment has been proved to regulate local tumor control, metastatic disease spreading as well as the occurrence of side effects. This Special Issue aims to place emphasis on the tumor microenvironment in the context of ionizing radiation therapies. Research areas may include fundamental mechanisms and signaling, translational or preclinical studies, bioengineering and technical breakthroughs. We welcome research articles, reviews offering comprehensive data or innovative opinions, (positive) clinical studies with direct targeting of the microenvironment, as well as in silico works, provided they highlight the contribution of non-tumor cells. We look forward to receiving your contributions promoting this exciting scientific field.

Guest Editor

Dr. Vincent Potiron

1. Institut de Cancérologie de l'Ouest, Département de Radiothérapie, 44800 Saint Herblain, France
2. CNRS UMR 6286, Université de Nantes, 44322 Nantes, France

Deadline for manuscript submissions

closed (1 May 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/117843

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)